Showing 2491-2500 of 3315 results for "".
- Alcon Expands TOTAL30 for Astigmatism Offerings with New Parametershttps://modernod.com/news/alcon-expands-total30-for-astigmatism-offerings-with-new-parameters-to-enhance-comfort-and-accessibility/2482553/Alcon announced the availability of expanded parameters for TOTAL30 for Astigmatism. As the first and only monthly replacement Water Gradient toric contact lens, TOTAL30 is designed to deliver a
- Ophtec Receives CE Mark Approval for Artiplus Phakic IOL for Presbyopiahttps://modernod.com/news/ophtec-receives-ce-mark-approval-for-artiplus-phakic-iol-for-presbyopia/2482548/Ophtec announced it has received CE Mark approval for its Artiplus Phakic IOL, which is designed for young presbyopes, typically in their early 40s. The Artiplus lens is designed to provide clear vision at all distances, eliminating the need for reading glasses or other corrective
- Atsena and Nippon Shinyaku Enter Strategic Collaboration for ATSN-101 Advancementhttps://modernod.com/news/atsena-therapeutics-and-nippon-shinyaku-enter-strategic-collaboration-for-atsn-101-advancement/2482542/Atsena Therapeutics has entered into an exclusive licensing agreement with Nippon Shinyaku for the commercialization of investigational gene therapy ATSN-101 for Leber congenital amaurosis. Atsena's ATSN-101 is a subretinal AAV5 gene therapy undergoing evaluatio
- Bausch + Lomb’s Recycling Programs Collect Over 94 Million Units of Eye Care Waste in the UShttps://modernod.com/news/bausch-lombs-recycling-programs-collect-over-94-million-units-of-eye-care-waste-in-the-us/2482541/Bausch + Lomb announced a milestone in its sustainability efforts—the company's exclusive recycling initiatives, ONE by ONE Recycling and Biotrue Eye Care Recycling programs, have successfully collected a total of 94,119,275 units of used contact lenses, eye care, and lens care material
- Tarsus Appoints Elizabeth Yeu, MD, as Chief Medical Officerhttps://modernod.com/news/tarsus-appoints-elizabeth-yeu-md-as-chief-medical-officer/2482527/Tarsus Pharmaceuticals announced the appointment of Elizabeth Yeu, MD, as chief medical officer, effective November 4, 2024. A distinguished ophthalmologist with more than two decades of clinical experience and leadership, Dr. Yeu has served as Tarsus’ chief medical advisor s
- FELIQS Receives FDA Fast Track Designation for FLQ-101, a First-in-Class Small Molecule to Prevent Retinopathy of Prematurityhttps://modernod.com/news/feliqs-receives-fda-fast-track-designation-for-flq-101-a-first-in-class-small-molecule-to-prevent-retinopathy-of-prematurity/2482526/FELIQS announced that the US Food and Drug Administration (FDA) has granted its lead asset, FLQ-101, Fast Track designation for the prevention of retinopathy of prematurity (ROP). The company plans to conduct a Phase1b/2 study of FLQ-101 (tROPhy-1 study) both in the United States and Ja
- EyePoint Pharma Announces Positive Interim Results for Duravyu in Phase 2 VERONA Trial for DMEhttps://modernod.com/news/eyepoint-pharma-announces-positive-interim-results-for-duravyu-in-phase-2-verona-trial-for-dme/2482516/EyePoint Pharmaceuticals reported interim 16-week data from its ongoing phase 2 VERONA clinical trial, which is assessing the investigational sustained delivery therapy Duravyu. The therapy, developed for patients with diabetic macular edema (DME), leverages a proprietary bioerodible Duraser
- Genentech Announces Phase 4 Results for Vabysmo in Treating DME Among Underrepresented Populationshttps://modernod.com/news/genentech-announces-phase-4-results-for-vabysmo-in-treating-dme-among-underrepresented-populations/2482514/Genentech revealed promising 1-year findings from its phase 4 ELEVATUM study for Vabysmo (faricimab-svoa) for diabetic macular edema (DME) in racial and ethnic groups typically underrepresented in clinical trials. Results presented at the American Academy of Ophthalmology (AAO) 2024 annual m
- Ripple Therapeutics Announces Evaluation and Licensing Agreements with Glaukoshttps://modernod.com/news/ripple-therapeutics-announces-evaluation-and-licensing-agreements-with-glaukos/2482502/Ripple Therapeutics announced a new evaluation and licensing agreement with Glaukos this week that aims to leverage Ripple’s patented technology platform to create sustained release implants of targeted therapeutics for both glaucoma and retinal diseases. Financial terms of the de
- Alcon to Showcase Latest Innovations at AAO 2024 Annual Meetinghttps://modernod.com/news/alcon-to-showcase-latest-innovations-at-aao-2024-annual-meeting/2482489/Alcon will unveil its latest clinical data and product innovations at the American Academy of Ophthalmology (AAO) 2024 annual meeting. Attendees, including ophthalmologists, surgical staff, researchers, and industry leaders, are invited to visit Alcon at booth #4008 for hands-on demonstrations an